Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High Five: Tislelizumab + Chemotherapy in PD-L1high Metastatic NSCLC
NCT07715396Phase 3Not yet recruiting
- Sponsor
- AIO-Studien
- Start
- Oct 2026
- Primary completion
- Oct 2031
- Countries
- 1
01
Overview
A Phase 3 trial of tislelizumab in non-small cell lung cancer (NSCLC), sponsored by AIO-Studien. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07715396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07715396.